(MedPage Today) — The use of romiplostim (Nplate) reduced treatment modifications due to chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers, a phase III randomized trial showed.
Among 165 patients, 84% of those…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.






